Category Archives: Biotechnology

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) had a rough trading day for Tuesday March 21 as shares tumbled 9.45%, or a loss of $-4.2 per share, to close at $40.25. After opening the day at $44.75, shares of Puma Biotechnology Inc traded as high as $44.85 and as low as $39.80. Volume was 947,068 shares over 8,315 trades, against an average daily volume of 991,915 shares and a total float of 36.95 million. As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.49 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $36.22 and 200-day SMA is $42.55. For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI. Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, … Continue reading →

By Crystal Kim The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far,suggesting that investors may be getting defensiveand they arent alone. Credit Suisse upgraded its rating on pharmaceuticals/biotechnology to Overweight from Market Weight on Tuesday. That said the Health Care Select Sector SPDR (XLV) is down 0.21% as of Tuesday afternoon. Broad market valuations and heightened risk for a short-term correction led Chief U.S. Equity Strategist Lori Calvasina to boost defensive exposure. Whats not to like valuations are slightly more attractive in the large-cap space and reasonable in small-cap, earnings momentum is so low that it could go only go up, flows are signaling a turnaround, and there are virtually no concerns about so-called crowding risk. She notes: In large cap, net buy ratings, mutual fund overweights, and hedge fund net exposure have all been slipping from the high end of their historical range. In small cap, our sell-side indicator is also elevated, while our mutual fund indicator is moving up, and our hedge fund indicator is falling toward past lows. Importantly, sell-side ratings have shown a significant correlation with relative … Continue reading →

Biotechnology has emerged as one of the most forward-looking fields of science in recent decades, and a large number of nations have set their sights on it as a long-term development pillar, given its wide range of applications and the leapfrogging of current information technology, which allows to further exploit its potential. Biotechnology has already proven to be an option for growth in multiple economic sectors, finding applications of high importance in sectors such as pharmaceuticals, food, veterinary, cosmetic, environmental, agricultural, energy, among others, which make it an opportunity for those developing countries in search of a boost for the progress of their economies. It is then in biotechnology that a country like Colombia, which occupies the second place after Brazil in world biodiversity, with around 10% of the fauna and flora of the planet, can find possibilities of great impact for its economic growth and technological development. However, it is not a simple challenge if one takes into account the little investment that, unfortunately, is destined for R&D in the country. For example, according to World Bank data for the year 2014, Colombia allocated about 0.2% of GDP for this purpose, an amount significantly lower than the world average … Continue reading →

SAN GABRIEL, California, March 20, 2017 /PRNewswire/ -- ChineseInvestors.com (CIIX) ('CIIX' or the 'Company'), the premier financial information website for Chinese-speaking investors, today announces that it has established and registered XiBiDi Biotechnology Co., Ltd. in the Pudong Free-Trade Area in Shanghai, with registered capital requirements of $1.45 million USD over the next 10 years. XiBiDi Biotechnology will focus on the online and offline sales of health products including hemp-derived CBD (cannabidiol) oil, as well as hemp-based food and beverages. Notably, the Chinese character 'XiBiDi' is homophonic to 'CBD' in English. "I am delighted about the establishment and registration of our new hemp company," says CIIX founder and CEO, Warren Wang. "XiBiDi Biotechnology is strategically located in the Pudong Free-Trade Area of Shanghai, China, where we have the opportunity to reach a consumer base of nearly 1.4 billion people. We believe that this large population affords XiBiDi an outstanding opportunity to be the provider of choice for natural hemp products." XiBiDi Biotechnology will be the operator of CIIX's recently launched CBD online store, http://www.ChineseCBDoil.com, which will primarily focus on selling, where legal, hemp-based CBD nutrient and health products to Chinese-speaking customers worldwide through the online retail process. CIIX is also in … Continue reading →

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning The continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively. Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment. To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example. iland haveworked with many companies in the healthcare, life sciences and biotech industries. Therefore, it knowsfrom experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world. >See also:10 trends that will influence cloud … Continue reading →

"For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development services and GMP manufacturing of a broad portfolio of Antibody:Drug Conjugate (ADC) and Protein:Drug Conjugate (PDC) projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody:Peptide Conjugates, Antibody:Dye Conjugates, PEGylated proteins, and other bioconjugates including Biobetters," said Muctarr Sesay, Ph.D., Chief Scientific Officer at Goodwin Biotechnology. "Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of bioconjugates. When including our experience in manufacturing vaccines for use in early- and late-stage clinical trials, we found the Minneapolis Medical Research Foundation project to be highly intriguing." "This is not an unusual approach for us when we initiate a project because we collaborate with many of our clients in the early stages of proof of concept/development by empirically recommending the appropriate processes to create a viable ADC or PDC candidate," Dr. Sesay continued. "We then blend that with a solutions-oriented approach to help our clients overcome significant challenges to ensure that the process for their candidate is robust, compliant, economical, and scalable." "We are proud to help advance the … Continue reading →

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) traded on unusually high volume on Mar. 17, as the stock gained 0.91% to close at $44.15. On the day, Puma Biotechnology Inc saw 2.2 million shares trade hands on 7,459 trades. Considering that the stock averages only a daily volume of 1.19 million shares a day over the last month, this represents a pretty significant bump in volume over the norm. Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances. The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $35.79, and its 200-day SMA $42.49. Puma Biotechnology Inc has a P/B ratio of 7.77. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Headquartered … Continue reading →

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy. JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies. The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve … Continue reading →

GENEREX BIOTECHNOLOGY CORPORATION (OTCMKTS:GNBT) Files An 8-K Material Modification to Rights of ... Market Exclusive Generex Biotechnology Corporation is a development-stage company. The Company is engaged primarily in the research and development of drug delivery systems and technologies. The Company is focused on its technology for the administration of ... Read more: GENEREX BIOTECHNOLOGY CORPORATION (OTCMKTS:GNBT) Files An 8-K Material Modification to Rights of ... - Market Exclusive … Continue reading →

Triad Business Journal College hires leader for Biotechnology Center of Excellence Triad Business Journal Our Biotechnology Center of Excellence will be key to Alamance County's economic development and we are excited to have an administrator with the depth and breadth of experience as Yonnie Butler, said President Algie Gatewood. His range of ... Original post: College hires leader for Biotechnology Center of Excellence - Triad Business Journal … Continue reading →